Curis (CRIS) Retained Earnings (2010 - 2026)
Curis' (CRIS) quarterly Retained Earnings came in at -$1.3 billion in Q2 2026, little changed on a YoY basis from -$1.3 billion in Q2 2025, and little changed quarter-over-quarter from -$1.3 billion in Q1 2026.
Analysis
Curis (CRIS) Retained Earnings (2010 - 2026) Analysis & Trends
Curis (CRIS) has reported Retained Earnings for 17 consecutive years, with -$1.3 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Retained Earnings changed 0.0% year-over-year to -$1.3 billion; the trailing twelve-month figure through Jun 2026 stood at -$1.3 billion (changed 0.0% YoY), and the FY2025 full-year result was -$1.2 billion, down 0.61% from the prior year.
- Retained Earnings held at -$1.3 billion in Q2 2026 per CRIS's latest filing, from -$1.3 billion in the prior quarter.
- Across five years, Retained Earnings topped out at -$1.1 billion in Q1 2022 and bottomed at -$1.3 billion in Q1 2025.
- Historically, Retained Earnings has averaged -$1.2 billion across 5 years, with a median of -$1.2 billion in 2024.
- The sharpest annual moves came in 2023 and 2026: Retained Earnings fell 8.26% in 2023, then changed 0.0% in 2026.
- Over 5 years, Retained Earnings stood at -$1.1 billion in 2022, then decreased by 4.13% to -$1.2 billion in 2023, then slipped by 3.63% to -$1.2 billion in 2024, then slipped by 0.61% to -$1.2 billion in 2025, then declined by 4.22% to -$1.3 billion in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$1.3 billion, -$1.3 billion, and -$1.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | -22.28 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 9.53 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 15.69 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 37.62 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 558.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 20.97 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Curis | 2.63 Mn | -2.99 Mn | - | -1.30 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.30 Bn |
| Mar 31, 2026 | -1.30 Bn |
| Dec 31, 2025 | -1.25 Bn |
| Sep 30, 2025 | -1.30 Bn |
| Jun 30, 2025 | -1.30 Bn |
| Mar 31, 2025 | -1.30 Bn |
| Dec 31, 2024 | -1.24 Bn |
| Sep 30, 2024 | -1.23 Bn |
| Jun 30, 2024 | -1.22 Bn |
| Mar 31, 2024 | -1.21 Bn |
| Dec 31, 2023 | -1.20 Bn |
| Sep 30, 2023 | -1.20 Bn |
| Jun 30, 2023 | -1.20 Bn |
| Mar 31, 2023 | -1.20 Bn |
| Dec 31, 2022 | -1.15 Bn |
| Sep 30, 2022 | -1.14 Bn |
| Jun 30, 2022 | -1.12 Bn |
| Mar 31, 2022 | -1.11 Bn |
| Dec 31, 2021 | -1.09 Bn |
| Sep 30, 2021 | -1.10 Bn |